Protocol Ledger

NCT03994471 · Phase III · RECRUITING

Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

Interventional Phase III clinical trial protocol NCT03994471 sponsored by Iperboreal Pharma Srl in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-14 Enrollment: 170 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03994471
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)170 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03994471
Protocol FieldVerified Registry Value
NCT IdentifierNCT03994471
Consolidated Lead SponsorIperboreal Pharma Srl
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment170 participants (ESTIMATED)
Registered Start Date2022-12-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03994471
Hospital Research SiteLocationSite Profile
Aarhus University HospitalAarhus, DenmarkOpen Hospital Dossier ->
Fondazione IRCCS CA' Granda Ospedale Maggiore PoliclinicoMilan, ItalyOpen Hospital Dossier ->
Azienda Ospedaliera Di PadovaPadova, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI